ALK announces FDA approval for its house dust mite sublingual allergy immunotherapy tablet (ACARIZAX® in Europe) – P&T Community
|
ALK announces FDA approval for its house dust mite sublingual allergy immunotherapy tablet (ACARIZAX® in Europe)
P&T Community ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for its house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet. The HDM … |
